Sars-Cov-2 virus and vaccination; biological and statistical framework.
COVID-19
/ pathology
COVID-19 Vaccines
/ immunology
Humans
Immunity, Cellular
/ immunology
Influenza Vaccines
/ immunology
Mass Vaccination
/ methods
Measles virus
/ immunology
Measles-Mumps-Rubella Vaccine
/ immunology
Orthomyxoviridae
/ immunology
SARS-CoV-2
/ immunology
Smallpox Vaccine
/ immunology
Vaccination
Vaccines, Attenuated
/ immunology
Variola virus
/ immunology
COVID-19
SARS-CoV-2
coronavirus
severe acute respiratory syndrome
vaccination
Journal
Expert review of vaccines
ISSN: 1744-8395
Titre abrégé: Expert Rev Vaccines
Pays: England
ID NLM: 101155475
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
pubmed:
10
8
2021
medline:
24
9
2021
entrez:
9
8
2021
Statut:
ppublish
Résumé
The Development of the SARS-CoV-2 virus vaccine and its update on an ongoing pandemic is the first subject of the world health agenda. First, we will scrutinize the biological features of the measles virus (MV), variola virus (smallpox virus), influenza virus, and their vaccines to compare them with the SARS-CoV-2 virus and vaccine. Next, we will discuss the statistical details of measuring the effectiveness of an improved vaccine. Amidst the pandemic, we ought to acknowledge our prior experiences with respiratory viruses and vaccines. In the planning stage of observational Phase-III vaccine effectiveness studies, the sample size, sampling method, statistical model, and selection of variables are crucial in obtaining high-quality and valid results.
Identifiants
pubmed: 34365880
doi: 10.1080/14760584.2021.1965884
pmc: PMC8425431
doi:
Substances chimiques
COVID-19 Vaccines
0
Influenza Vaccines
0
Measles-Mumps-Rubella Vaccine
0
Smallpox Vaccine
0
Vaccines, Attenuated
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM